Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells

Prostate

Volumn 47, Issue 3, 2001, Pages 194-204

  Taj, Mary M ^a   Tawil, Rana J ^a   Engstrom, Lars D ^a   Zeng, Zhi ^a   Hwang, Clara ^a   Sanda, Martin G ^a   Wechsler, Daniel S ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Adenovirus; c Myc; Chromosome 10; G2 M arrest; Prostate cancer

Indexed keywords

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CHROMOSOME 10Q; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL DIVISION; DNA-BINDING PROTEINS; FLOW CYTOMETRY; G2 PHASE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICROSCOPY, CONFOCAL; MITOSIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0035873856     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.1063     Document Type: Article

References (58)

1. Cancer statistics, 1998
2. Molecular advances in prostate cancer
3. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia
4. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers
5. p53 and c-myc expression in stage A1 prostatic adenocarcinoma: Useful prognostic determinants?
6. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization
7. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization
8. The c-myc story: Where we've been, where we seem to be going
9. The molecular role of Myc in growth and transformation: Recent discoveries lead to new insights
10. Amplification, rearrangement, and elevated expression of c-myc in the human prostatic carcinoma cell line LNCaP
11. Transcriptional down-regulation of c-myc in human prostate carcinoma cells by the synthetic androgen mibolerone
12. Oncogene overexpression and de novo drug-resistance in human prostate cancer cells
13. Effects of sex steroids on cell growth and c-myc oncogene expression in LNCaP and DU-145 prostatic carcinoma cell lines
14. Transgenic models for the study of prostate cancer
15. Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein
16. Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: A novel therapy in prostate cancer
17. Antisense c-myc retroviral vector suppresses established human prostate cancer
18. Prostate cancer
19. c-Myc target genes involved in cell growth, apoptosis, and metabolism
20. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites
21. Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity
22. Mad3 and Mad4: Novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation
23. An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3
24. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1
25. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression
26. Gene-target recognition among members of the myc superfamily and implications for oncogenesis
27. Suppression of Myc, but not E1a, transformation activity by Max-associated proteins, Mad and Mxi1
28. Evolutionary relationships and functional conservation among vertebrate Max-associated proteins: The zebra fish homolog of Mxi1
29. Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells
30. Differential regulation of Max and role of c-Myc during erythroid and myelomonocytic differentiation of K562 cells
31. Sequential expression of the MAD family of transcriptional repressors during differentiation and development
32. MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells
33. Metastasis suppressor genes for prostate cancer
34. Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10
35. Localization of the human Mxi1 transcription factor gene (MXI1) to chromosome 10q24-q25
36. Mapping of two genes encoding members of a distinct subfamily of MAX interacting proteins: MAD to human chromosome 2 and mouse chromosome 6, and MXI1 to human chromosome 10 and mouse chromosome 19
37. Assignment of the human MAD and MXI1 genes to chromosomes 2p12-p13 and 10q24-q25
38. Frequency and pattern of karyotypic abnormalities in human prostate cancer
39. Allelic loss of chromosomes 16q and 10q in human prostate cancer
40. Cytogenetic analysis of 57 primary prostatic adenocarcinomas
41. Allelic loss on chromosome 10 in prostate adenocarcinoma
42. Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer
43. Mutation of the MXI1 gene in prostate cancer
44. Commonly occurring loss and mutation of the MXI1 gene in prostate cancer
45. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth
46. Isolation of a human prostate carcinoma cell line (DU 145)
47. Characterization of chromosome changes in two human prostatic carcinoma cell lines (PC-3 and DU145) using chromosome painting and comparative genomic hybridization
48. Transfer of genes to humans: Early lessons and obstacles to success
49. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
50. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
51. Two MAD tails: What the recent knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/ MAD network
52. Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells
53. Delayed cyclin B1 expression during the G2 arrest following DNA damage
54. Butyrolactone I induces cyclin B1 and causes G2/M arrest and skipping of mitosis in human prostate cell lines
55. Mxi1 is a repressor of the c-Myc promoter and reverses activation by USF
56. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
57. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations
58. Cdc25 cell-cycle phosphatase as a target of c-myc